BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. J Med Econ 2020;23:786-99. [PMID: 32149541 DOI: 10.1080/13696998.2020.1740236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
2 Jiang M, Near AM, Desta B, Wang X, Hammond ER. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015. Lupus Sci Med 2021;8:e000503. [PMID: 34521733 DOI: 10.1136/lupus-2021-000503] [Reference Citation Analysis]
3 Thompson JC, Mahajan A, Scott DA, Gairy K. The Economic Burden of Lupus Nephritis: A Systematic Literature Review. Rheumatol Ther 2021. [PMID: 34731412 DOI: 10.1007/s40744-021-00368-y] [Reference Citation Analysis]
4 Jakovljevic M, Tan CJ, Chaiyakunapruk N, Silva Julian G, Cheung KL, Hiligsmann M, Godman B, Opanga S, Scuffham PA, Gregg M. Global article collection: essential reads from around the world. J Med Econ 2022;25:864-9. [PMID: 35678118 DOI: 10.1080/13696998.2022.2087960] [Reference Citation Analysis]
5 Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol 2021;31:1-12. [PMID: 32814461 DOI: 10.1080/14397595.2020.1812201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]